SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of ARIAD Pharmaceuticals, Inc., (Nasdaq: ARIA) violated state or federal laws.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) disclosed on October 9, 2013 that its drug Iclusig causes more side effects than earlier communicated. Following discussions with the U.S. Food and Drug Administration (FDA), ARIAD has halted enrollment in all ongoing Iclusig clinical trials and will advise current patients on the drug to lower the dose.
ARIAD shares are down over 74% in early morning trading on the announcement.
Johnson & Weaver’s investigation will seek to determine if investors or regulators were previously misled by ARIAD’s officers or directors concerning Iclusig’s potential side effects.
If you have information that could assist in this investigation, or if you are an ARIAD shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (email@example.com) by email or by phone at 619-230-0063, Ext.118.
Johnson & Weaver, LLP is a nationally recognized shareholders’ rights law firm. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com.